Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies
Abstract Background Autoimmune encephalitis (AE) with neuronal surface antibodies (NSAbs) presents pathogenesis mediated by B cell-secreting antibodies. Rituximab is a second-line choice for the treatment for AE with NSAbs, which can cause B cell depletion via targeting CD20. However, the optimal pr...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-10-01
|
Series: | Journal of Neuroinflammation |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12974-022-02622-8 |